May
Drug Discovery Biology
&
Bioinformatics
Strategy Meeting East Coast USA 2024
Pushing our understanding of the physiological context and quality of drug target characterisation, validation, and safety profiling throughout the preclinical space
What makes our strategy meetings unique?
Roundtable Discussions
Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.
Unrivalled Networking
With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.
Personalised Agenda
Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.
Solutions to your Problems
We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.
Industry Researched Topics
We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.
Senior Decision Makers
The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.
Meet Our Facilitators
Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our upcoming strategy meeting.
Aaron Mackey
Former SVP, AI & Data Science Sonata TherapeuticsAbhijat Vatsyayan
Head of Artificial Intelligence Taiho OncologyAndrew Zhang
Director, Head of Chemical Biology AstraZenecaAngela Huang
Founder and President Tempo BioscienceChristopher Conway
President, Research and Development CuriaClaudette Fuller
Vice President, Head of Non-Clinical Safety & Toxicology GenmabDouglas Kitchen
Research Fellow, Medicinal Chemistry CuriaErnane Souza, PhD, RPh
Assistant Director, Translational PKPD and DMPK Supernus Pharmaceuticals IncFrank Leu
Founder & Managing Member/ Managing Member BioPharMatrix LLC/ Novapeutics LLCGreg Williams
Senior Research Scientist II, Cellular Assay Technologies CuriaDr. Grant Carr
Vice President, Head of Global R&D Drug Discovery CuriaGunaretnam Rajagopal
Venture Partner Samsara BiocapitalMarcie Glicksman
Vice President, Biology Enclear TherapiesMark Tornetta
VP of Biologics Discovery Tavotek BiotherapeuticsML Ujwal
Associate Director, Data Science R&D J&J USNikolaos Tezapsidis
President & CEO Neurotez Inc.Paul Kayne
Vice President, Biological Sciences Palatin TechnologiesSee Which Topics Are Discussed at the Strategy Meeting
Mechanistic understanding of E3 ligase engagement: Yesterday’s news or hidden secrets?
Roundtable Tracks
1Maximizing The Potentials Of Multiomics In Target Identification And Safety Profiling
-Paul Kayne
Vice President, Biological Sciences
Palatin Technologies
DMPK / ADME & Toxicology
Advancing Drug Discovery and Safety Assessment with AI/ML: Where We Are And Where We Re Going
-Claudette Fuller
Vice President, Head of Non-Clinical Safety & Toxicology
Genmab
In Vivo and In Vitro Pharmacology
Latest Approaches And Trends For Improving Nonclinical Studies
-Angela Huang
Founder and President
Tempo Bioscience
In Silico Biology / AI & ML / Blockchain and Bioinformatics Data Integration / Data Mining
Harnessing The Promise Of Generative AI To Transform Drug Discovery Hence Forward
-Aaron Mackey
Former SVP, AI & Data Science
Sonata Therapeutics
Strategic Partnerships, Investment & Collaborations
Forming Strategic Partnerships:
Collaboration or M&A?
-Nikolaos Tezapsidis
President & CEO
Neurotez Inc.
Roundtable Tracks
2Probing ways to access greater target space and expand the druggable genome to a larger therapeutic area to discover new drugs
-Greg Williams
Senior Research Scientist II, Cellular Assay Technologies
Curia
Curia
DMPK / ADME & ToxicologyIntegrating Breakthroughs In In Silico In Vivo And In Vitro Pharmacology To Enhance ADMET Modeling
-Dr. Grant Carr
Vice President, Head of Global R&D Drug Discovery
Curia
Curia
In Vivo and In Vitro PharmacologyIn Silico Biology / AI & ML / Blockchain and Bioinformatics Data Integration / Data Mining
Leveraging AI Target Selection Technologies Strategies And Infrastructure Tools To Support Computational Biology
-Douglas Kitchen
Research Fellow, Medicinal Chemistry
Curia
Curia
Strategic Partnerships, Investment & CollaborationsStrategic Partnerships, Investment & Collaborations in drug development
-Frank Leu
Founder & Managing Member/ Managing Member
BioPharMatrix LLC/ Novapeutics LLC
Roundtable Tracks
3Reducing Attrition Rate By Employing Groundbreaking Technologies At Discovery Stage And Accelerate The Process
-Mark Tornetta
VP of Biologics Discovery
Tavotek Biotherapeutics
DMPK / ADME & Toxicology
In Vivo and In Vitro Pharmacology
Tackling In Vivo Complexity: Strategies for Overcoming Assay Challenges
-Marcie Glicksman
Vice President, Biology
Enclear Therapies
In Silico Biology / AI & ML / Blockchain and Bioinformatics Data Integration / Data Mining
Current Adoption And Best Use Of Disruptive Techs (Blockchain, AI And ML) In Drug Discovery And Development
-Frank Leu
Founder & Managing Member/ Managing Member
BioPharMatrix LLC/ Novapeutics LLC
Strategic Partnerships, Investment & Collaborations
Strategic Partnerships in Drug Discovery: Navigating Pharma-Biotech Ecosystems and Industry-Academia Alliances
-ML Ujwal
Associate Director, Data Science
R&D J&J US
Intellectual property development in an artificially intelligent world
Roundtable Tracks
4Navigating Target Selection and Validation in Drug Discovery: Criteria, Strategies and Models
-Marcie Glicksman
Vice President, Biology
Enclear Therapies
DMPK / ADME & Toxicology
Artificial Intelligence, ADME/Tox prediction,PBPK modeling, and Data ManagementStrategies for early drug development.
-Ernane Souza, PhD, RPh
Assistant Director, Translational PKPD and DMPK
Supernus Pharmaceuticals Inc
In Vivo and In Vitro Pharmacology
In Silico Biology / AI & ML / Blockchain and Bioinformatics Data Integration / Data Mining
Leveraging AI to Accelerate Drug Discovery and Development
-Abhijat Vatsyayan
Head of Artificial Intelligence
Taiho Oncology
Strategic Partnerships, Investment & Collaborations
Fundraising and Partnership Opportunitiesin the current BioPharma Industry
-Angela Huang
Founder and President
Tempo Bioscience
Tackling the pros and cons of different financing blueprint: go-to-clinic vs go-to-market vs go-to-fundraising strategies and the criteria to determine which program an organization can adapt
Reasons To Attend Our Strategy Meetings
Fully Interactive Format
There’s only so much you can learn from presentations and lectures. Instead our interactive Roundtable Discussions let you debate the topics that really matter
Senior Decision Makers
All our Strategy Meetings are aimed at director level and above. Discover how your peers are tackling the industries biggest challenges and have your thoughts heard
Personalised Agendas
Pick the roundtable discussions that you want to be part of. Simply choose your sessions and we’ll create a personalised agenda just for you
Private and Intimate Networking
Small group discussions, private meetings, networking drinks – however you choose to make those important connections our Strategy Meetings have the solution
Testimonials
Hotel & Venue
Hyatt Regency Princeton
Hyatt Regency Princeton hotel is conveniently located near corporate offices and attractions, as well as the Mercer County Airport.
Hotel Details Map & Directions ParkingHere To Help
Need help registering your team? Just get in touch and a member of the team will be happy to help.